Stevanato Group SpA, a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, has announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina pen injector platform have received marketing authorisations in Europe.
The authorisations relate to finished combination products held by the respective marketing authorisation holders.
The approved configurations include Alina 30, developed for liraglutide-based therapies for diabetes, and Alina 50, designed for liraglutide-based weight management applications.
Both variants are part of Stevanato Group’s broader Alina variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1s and other injectable therapies.
Alina features a dial-a-dose mechanism with visual, audible, and tactile feedback during dose selection and injection, and compatibility with ISO standard 3 mL glass cartridges.
The platform has been designed to support manufacturing scalability, and integration into existing pharmaceutical fill and finish and final assembly supply chains.
These authorisations come at a time when injectable therapies are playing an increasingly important role in healthcare, driven by the ongoing expansion of GLP-1 treatments and the broader shift towards patient-centric models of care and self-administration. Through its proprietary device portfolio – including Alina (variable-dose, pen injector), Deora (fixed-dose, pen injector), Aidaptus (autoinjector) and Vertiva (on-body delivery system) – Stevanato Group is expanding its drug delivery capabilities to support pharmaceutical and biotechnology companies developing next-generation therapies.
Alina is manufactured within Stevanato Group’s Drug Delivery Systems operations and leverages the company’s integrated expertise across pharmaceutical glass containers, engineering technologies, analytical services and device manufacturing.
The platform has been designed to offer pharmaceutical partners a flexible and production-ready solution capable of supporting commercial-scale deployment.